MAPREG
- | Biotech or pharma, therapeutic R&D
MAPREG is a clinical-stage biotechnology company operating in the CNS field;
our mission is to bring first-in-class disruptive medicines to market, to change the lives of patients suffering challenging psychiatric indications such as Treatment Resistant Depression.
Our technology uniquely triggers neuroplasticity at core, via the neuronal microtubules, engaging a totally novel biological pathway that no other company is able to target.
Our phase 2 data from 110 TRD patients show a remarkable differentiated profile of activity coupled to a very high tolerance.
We are launching a series B round to propel our technology towards market in TRD, expand our value to related neuropsychiatric diseases where neuroplasticiy is key, offering partnering opportunities as well.
Address
Le Kremlin-BicêtreFrance
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}